TPTX Turning Point Therapeutics, Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyís lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naÔve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointís kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

$35.93  -2.87 (-7.40%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/17/2019
Outstanding shares:  49,479,508
Average volume:  422,657
Market cap:   $1,919,804,910
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    90041T108
ISIN:        US90041T1088
Sedol:      BJXBP30
Valuation   (See tab for details)
PE ratio:   -8.63
PB ratio:   1.74
PS ratio:   62.27
Return on equity:   -20.20%
Net income %:   -666.51%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy